As persistent circulating SARS‐CoV‐2 spike protein is detected in COVID‐19 patients' blood samples and is associated with post‐acute sequelae of COVID (Swank et al, 2023), CLEC2.Fc may bind the circulating SARS‐CoV‐2 spike protein to prevent the activation of platelets and alveolar macrophages, thereby attenuates SARS‐CoV‐2‐induced thromboinflammation in lung. The gene discussed is CLEC1B; the disease is COVID-19.